Challenges Facing the Immuno-Oncology Pipeline
The global Immuno Oncology (IO) market is on a transformative growth trajectory, anticipated to reach $129.18 billion by 2032 at a CAGR of 20.0%. The market’s momentum is reinforced by technological innovations, increasing cancer incidence, growing preference for personalized treatment
